A phase II study of weekly oral methotrexate and zidovudine (AZT) in advanced adenocarcinoma of the pancreas and hepatocellular carcinoma.

摘要: From January 1992 through May 1993, 31 patients with adenocarcinoma of the pancreas or hepatocellular carcinoma were treated weekly oral methotrexate (7.5 mg/M2 every 6 hours for doses) and continuous AZT (200 mg four times daily). Patients a total months until disease progression. The median age was 66 (range 44–79) KPS 80. No patient had received prior chemotherapy. Hematologic toxicity severe 50% developing hemoglobins less than 8 gm/dl 70% granulocyte counts 1000 per mm3. One achieved radiographic complete remission 2 stable disease. Two-thirds progressed within beginning therapy. combination is an inactive regimen in pancreatic associated considerable toxicity.